News archive

June 2015

• • June 22, 2015
  • Crown Bioscience

  Crown Bioscience Expands Life Science Product Offering with Recombinant Cell Lines

  EML4-ALK, PD-1, PD-L1, AND WNT CELL LINES FOR BIOLOGICAL STUDIES AND DRUG SCREENING

• • June 19, 2015
  • Crown Bioscience

  Crown Bioscience Reveals Strategy for Combining Drug Therapy with Irradiation to Overcome Resistance to Oncology Ther...

  Novel Strategies For Combining Drug Therapy With Irradiation To Deliver New Hope For Overcoming Resistance In The Clinic

March 2015

• • March 3, 2015
  • Crown Bioscience

  Crown Bioscience Launches Life Science Product Catalog

  TOOLS TO SUPPORT PRECLINICAL RESEARCH, DRUG DEVELOPMENT AND VALIDATION

February 2015

• • February 12, 2015
  • Crown Bioscience

  Crown Bioscience Acquires Molecular Response’s Patient Derived Xenograft (PDX) Business

  Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryo...

January 2015

• • January 15, 2015
  • Crown Bioscience

  Crown Bioscience Announces First European Symposium on Translational Oncology and the use of Patient-Derived Xenograf...

  KEY OPINION LEADERS TO DISCUSS THE USE OF TRANSLATIONAL PLATFORMS IN ACCELERATING ONCOLOGY DRUG DISCOVERY

October 2014

• • October 20, 2014
  • Crown Bioscience

  Crown Bioscience Announces U.S. Expansion With New Translational Oncology Center

  NEW SERVICE CENTER WILL ALLOW THE EXPANSION OF NEW IMMUNOTHERAPY EXPERIMENTAL PLATFORMS TO ADVANCE TRANSLATIONAL MEDICAL RESEARCH AND THE TREATMENT OF CANCERS

August 2014

• • August 14, 2014
  • Crown Bioscience

  Crown Bioscience Announces Inaugural Symposium to Foster Greater Understanding of Predictive Models in Oncology

  INDUSTRY LEADERS WILL DISCUSS USE OF PATIENT-DERIVED XENOGRAFT MODELS TO HELP ACCELERATE ONCOLOGY DRUG DISCOVERY

May 2014

• • May 15, 2014
  • Crown Bioscience

  Crown Bioscience receives $26.55 million in Series D Funding

  INVESTMENT TO FUND RAPID EXPANSION IN TRANSLATIONAL PLATFORM TECHNOLOGIES FOR ONCOLOGY AND METABOLIC DISEASES

• • May 8, 2014
  • Crown Bioscience

  Crown Bioscience Announces Research Collaboration with the National Resource Center for Mutant Mice (NRCMM)

  NEW COLLABORATION AIMS TO DEVELOP DISEASE-SPECIFIC EXPERIMENTAL MODELS FOR TRANSLATIONAL MEDICAL RESEARCH

April 2014

• • April 24, 2014
  • Crown Bioscience

  Crown Bioscience Enters Japanese Market via Strategic Partnership with Shin Nippon Biomedical Laboratories

  While Crown is the world’s leading supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific, Japan is seen as a market with ...

• • April 22, 2014
  • Crown Bioscience

  Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

  SIZE OF COLLECTION ALLOWS FOR MORE INFORMED PRECLINICAL DECISION MAKING ON PROSPECTIVE DRUG CANDIDATES

November 2013

• • November 26, 2013
  • Crown Bioscience

  Shanghai Institute of Materia Medica and Crown Bioscience Reach Landmark Agreement to Develop World-leading Mouse Cli...

  With this joint effort, the Center will dramatically expand the combined operational capacity to support global translational oncology efforts, particularly mouse clinical trial (HuTrialTM platform...